for obstructive hypertrophic cardiomyopathy (HCM)
FDA approved Myqorzo (aficamten) on December 19, 2025 — ~1 week ahead of the extended PDUFA — for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Second-in-class cardiac myosin inhibitor after BMS's Camzyos (mavacamten). Available in 5/10/15/20 mg doses.
Myqorzo (aficamten) is a pill that works by directly calming the overactive heart muscle, reducing its excessive squeezing force. This mechanism targets the fundamental cause of the obstruction and stiffness in symptomatic obstructive HCM. For patients, this may improve their ability to exercise and reduce symptoms like shortness of breath.
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Source: ClinicalTrials.gov